Opioid-induced constipation (OIC) is the most common side effect of opioid therapy because of the distribution of opioid receptors throughout the GI tract. Although OTC treatment for OIC is common, patients with more-severe symptoms often move to prescription drug therapy. The OIC drug market includes FDA-approved mu opioid receptor antagonists: Shionogi’s Symproic, Salix’s Relistor, and AstraZeneca / Daiichi Sankyo’s Movantik. Other therapies with alternative MOAs approved or in late-phase development include Allergan / Ironwood’s Linzess, a guanylate cyclase-C agonist; Mallinckrodt’s Amitiza, a bicyclic fatty acid; and Takeda’s Motegrity, a 5-HT4-receptor agonist. Given the number of agents now available / in development for OIC, understanding how and where each is positioned in the treatment algorithm is increasingly important as developers work to differentiate their product from the competition.
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed OIC patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed OIC patients?
- How have the mu opioid receptor antagonists been integrated into the treatment algorithm, and what is their source of business?
- What percentage of OIC patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of OIC patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
- Opioid Induced Constipation - Current Treatment - Detailed, Expanded Analysis - Treatment Algorithms - Claims Data Analysis (US)
Author(s): Maria Genco, Ph.D
Maria Genco, Ph.D., is an analyst on the Immune and Inflammatory Disorders group at Decision Resources Group, primarily focusing on rheumatoid arthritis and axial spondyloarthritis. She has authored market research reports on the RA disease landscape and commercial outlook of drugs, unmet needs in RA, and market access and reimbursement for RA targeted therapies. Prior to joining Decision Resources, Dr. Genco received her M.S. and Ph.D. in neuroscience from Brandeis University and a B.A. in neuroscience from Wellesley College.